Guided Therapeutics Inc  

(Public, OTCBB:GTHP)   Watch this stock  
Find more results for OTC:GTHP
+0.005 (4.90%)
Delayed:   3:02PM EDT
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.09 - 0.10
52 week 0.07 - 0.55
Open 0.10
Vol / Avg. 315,299.00/627,178.00
Mkt cap 11.21M
P/E     -
Div/yield     -
EPS -0.13
Shares 100.89M
Beta 0.32
Inst. own 9%
May 14, 2015
Q1 2015 Guided Therapeutics Inc Earnings Call
May 13, 2015
Q1 2015 Guided Therapeutics Inc Earnings Release
Mar 26, 2015
Q4 2014 Guided Therapeutics Inc Earnings Call
Mar 25, 2015
Q4 2014 Guided Therapeutics Inc Earnings Release

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -1728.65% -1200.85%
Operating margin -1337.30% -1092.83%
EBITD margin - -902.67%
Return on average assets -379.89% -311.42%
Return on average equity - -
Employees 33 -
CDP Score - -


5835 Peachtree Cors E Ste D
NORCROSS, GA 30092-3413
United States - Map
+1-770-2428723 (Phone)

Website links


Guided Therapeutics, Inc. is a medical technology company focused on developing medical devices. The Company’s primary focus is the development of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, especially esophageal. The Company’s technology, including products in research and development, primarily relate to biophotonics technology for the non-invasive detection of cancers. LuViva is a non-invasive cervical cancer detection product, based on the Company's biophotonic technology. The device is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point-of-care by scanning the cervix with light, then analyzing the light reflected or emanating from the cervix. The Company's product, in addition to detecting the structural changes attributed to cervical cancer, is also designed to detect the biochemical changes that precede the development of visual lesions.

Officers and directors

Michael C. James Independent Chairman and Director
Age: 56
Gene S. Cartwright Ph.D. Chief Executive Officer, Acting Chief Financial Officer, President and Director
Age: 61
Richard L. Fowler Senior Vice President - Engineering
Age: 58
Ronald W. Hart Independent Director
Age: 73
John E. Imhoff M.D. Independent Director
Age: 66
Jonathan M. Niloff M.D. Independent Director
Age: 61
Linda M. Rosenstock M.D. Independent Director
Age: 64